Arthritis & Rheumatology最新文献

{"title":"Treatment-Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of ESSDAI and STAR Response to B Cell Therapy in Sjögren's Disease.","authors":"Aimen Ibrahim, Junjie Peng, Eileen Tian, Lucia Martin-Gutierrez, John Casement, Kyle Thompson, Wan-Fai Ng, André van Maurik, Elizabeth C Jury, Coziana Ciurtin","doi":"10.1002/art.70354","DOIUrl":"10.1002/art.70354","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to characterize whole blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti-CD20 or B lymphocyte stimulator/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to nonresponse.</p><p><strong>Methods: </strong>Whole blood RNA sequencing was performed at baseline and Week 24 in participants (n = 43) from a phase 2 GSK trial (NCT02631538) evaluating rituximab (RTX), belimumab (BEL), and sequential BEL-RTX versus placebo. Differential expression (DESeq2; fold change >1.5; unadjusted P < 0.01) was integrated with pathway enrichment and ligand-receptor analyses (Metascape, gene set enrichment analysis, curated interaction databases). Clinical response was defined using EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) and Sjögren's Tool for Assessing Response (STAR); responder groups were compared using descriptive statistics, correlations, and logistic regression with receiver operating characteristic-based evaluation.</p><p><strong>Results: </strong>Sequential BEL-RTX induced the largest transcriptional shift from baseline to Week 24. Baseline differential expression identified distinct ligand-receptor predictors for each response definition. ESSDAI nonresponse was associated with higher baseline transforming growth factor β-2 (TGFβ-2), C4A, and CD8A expression, and lower complement component 4 BP alpha (C4BPA) expression, defining complement-regulated, cytotoxic, and stromal-remodeling pathways (area under the curve [AUC] 0.89). In contrast, STAR nonresponders showed higher baseline expression of SPP1, TLR4, IL1R1, IL18R1, IL1RAP, TREM1, and FCGR2A, forming an IL-1/IL-18/FcγR-centered myeloid module (AUC 0.80). No ligand-receptor genes overlapped between ESSDAI and STAR. ESSDAI genes clustered nonresponders distinctly, whereas STAR genes showed weak separation with no cluster concordance between the two response definitions.</p><p><strong>Conclusion: </strong>The distinct ESSDAI and STAR ligand-receptor signatures indicate different systemic biologic drivers of nonresponse to B cell therapies in SjD. Their complete nonoverlap suggests entrenched B cell-independent inflammatory circuits, highlighting complement regulation, TGFβ-2-mediated remodeling, IL-1/IL-18 signaling, and FcγR activation as rational treatment pathways beyond B cell-targeted therapies.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MDL-800-induced SIRT6 activation decreases age-associated osteoarthritis in mice.","authors":"Matheus Moreira Perez, Pranay Ramteke, Bahiyah Watson, Owen Haslam, Eirene Choi, Susan Chubinskaya, Mandy J Peffers, William R Davis, Jacqueline Shine, Brian O Diekman, Richard F Loeser, Theresa A Freeman, Makarand V Risbud, John A Collins","doi":"10.1002/art.70342","DOIUrl":"10.1002/art.70342","url":null,"abstract":"<p><strong>Objective: </strong>SIRT6 is a nuclear-localized histone deacetylase that regulates multiple pathways associated with aging. This study aimed to determine whether systemic administration of a small molecule activator of SIRT6, MDL-800, decreases the severity of age-associated osteoarthritis (OA) in mice.</p><p><strong>Methods: </strong>Male 18-month-old mice received weekly intraperitoneal injections of MDL-800 or vehicle control for 6 months, and OA severity was assessed at 24 months using histology, micro-CT, and histomorphometry. The role of MDL-800-induced SIRT6 activation in human chondrocyte function was analyzed using RNA sequencing and immunoblotting. The effect of MDL-800 to reduce DNA damage was assessed in human and mouse synovial fibroblasts by the comet assay.</p><p><strong>Results: </strong>Mice receiving long-term administration of MDL-800 were protected from OA pathology when compared to controls, as characterized by less cartilage damage, osteophyte formation, synovial hyperplasia, subchondral bone sclerosis, and meniscal ossification. RNA sequencing of chondrocytes revealed that MDL-800 negatively enriched pathways associated with bone formation, angiogenesis, and catabolic MAP kinase signaling, while positively enriching pathways associated with epigenetic regulation, telomere maintenance, mitochondrial function, redox balance, and DNA repair. MDL-800 significantly decreased oxidative stress-induced phosphorylation of p38 in chondrocytes and basal DNA damage in human and mouse synovial fibroblasts.</p><p><strong>Conclusions: </strong>Activation of SIRT6 by MDL-800 significantly protected old mice from age-associated OA severity in vivo. MDL-800 decreased pathways associated with pathological bone formation and regulated multiple hallmarks of aging. Targeted therapies that activate SIRT6 may represent a novel strategy to repress multiple aging pathways to slow, stop, or reverse age-associated OA.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug‐Free Remission in Early Peripheral Spondyloarthritis, including Psoriatic Arthritis: 10‐year follow‐up from the CRESPA trial","authors":"Caroline Damen, Ann‐Sophie De Craemer, Casper Webers, Dirk Elewaut, Gaelle Varkas, Filip Van den Bosch, Philippe Carron","doi":"10.1002/art.70349","DOIUrl":"https://doi.org/10.1002/art.70349","url":null,"abstract":"Objectives To provide a descriptive analysis of the 10‐year follow‐up data from the CRESPA study. Here, patients fulfilling the ASAS peripheral spondyloarthritis (pSpA) classification criteria, with symptom duration ≤12 weeks, were randomized to golimumab 50mg Q4W or placebo. Our aims were to assess the proportion of patients in (drug‐free) clinical remission and identify baseline predictors of achieving (drug‐free) remission at 10‐year follow‐up. Methods All patients from the original CRESPA study were invited for a standardized evaluation 10 years after inclusion. Clinical remission was defined as the absence of swollen joints, enthesitis or dactylitis. Results Of 60 original patients, 49 were evaluated after a mean of 10.5 years (SD 0.87). 81.6% (40/49) of patients were in clinical remission, of whom 30.6% (15/49) achieved longstanding drug‐free remission. Remission was not linked to baseline characteristics like sex, age, HLA B27‐positivity, psoriasis or initial treatment allocation. Patients without psoriasis at baseline were significantly more likely to achieve drug‐free remission (OR 9.1; 95% CI 1.8–50), with 48.1% (13/27) non‐psoriatic pSpA patients remaining in drug‐free remission. Health‐related quality of life and physical function was significantly better in patients in remission. Conclusion Remission induction with golimumab in patients with early pSpA enables achievement of sustained clinical remission in the majority of patients with one‐third of patients attaining drug‐free remission. Strikingly, almost half of non‐psoriatic pSpA remained in drug‐free remission. These findings strongly suggest that early, intensive treatment has the potential to achieve long‐term disease control, potentially leading to sustained drug‐free remission in a subset of patients.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"395 2 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149010080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.","authors":"Francesco Baldo, Greta Rogani, Remco G A Erkens, Mao Mizuta, Claudia Bracaglia, Dirk Foell, Marco Gattorno, Marija Jelusic, Jordi Anton, Paul Brogan, Scott Canna, Shanmuganathan Chandrakasan, Randy Q Cron, Fabrizio De Benedetti, Alexei Grom, Merav Heshin-Bekenstein, AnnaCarin Horne, Raju Khubchandani, Seza Ozen, Pierre Quartier, Angelo Ravelli, Masaki Shimizu, Grant Schulert, Christiaan Scott, Rashmi Sinha, Nicolino Ruperto, Joost F Swart, Sebastiaan Vastert, Francesca Minoia","doi":"10.1002/art.70348","DOIUrl":"https://doi.org/10.1002/art.70348","url":null,"abstract":"<p><strong>Objective: </strong>Macrophage Activation Syndrome (MAS) is a rare, life-threatening hyperinflammatory condition complicating rheumatologic diseases, most commonly Still's disease (SD). Despite increasing awareness and emerging recommendations, MAS treatment remains heterogeneous worldwide. The METAPHOR project aimed to describe real-life therapeutic strategies for MAS, exploring differences across underlying diseases, geographic regions, physician subspecialties, and drug availability.</p><p><strong>Methods: </strong>An international web-based survey was developed by a multidisciplinary expert panel together with a patient representative, following a systematic literature review. The survey was anonymously completed through PReS/PRINTO and the Histiocyte Society networks (October-December 2023). Treatment strategies for MAS across different rheumatologic contexts were explored. Responses were analyzed descriptively and stratified by geography, subspecialty, clinical experience, and underlying disease.</p><p><strong>Results: </strong>A total of 287 physicians from 64 countries completed the survey, the majority being pediatric rheumatologists with more than 5 years of experience. Glucocorticoids, particularly intravenous methylprednisolone, were consistently identified as 1^st-line therapy across all MAS subtypes (for 44% of clinicians as monotherapy). Anakinra, ciclosporin, and intravenous immunoglobulins were the most frequently combined agents. However, their use varied markedly by underlying disease and geographical region, with anakinra preferentially used in SD-MAS. Striking global disparities in drug availability, particularly for anakinra and emapalumab, significantly influenced treatment choices and were associated with increased reliance on steroid monotherapy.</p><p><strong>Conclusion: </strong>MAS management remains highly heterogeneous worldwide. While glucocorticoids remain foundational, reducing steroid reliance through equitable access to immunomodulatory therapies and advancing mechanism-based strategies represent critical priorities in optimizing MAS care.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149011659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aryl Hydrocarbon Receptor regulates uric acid homeostasis","authors":"Jeremy Zaworski, Ellie Tang, Jennifer Kervadec, Jeremy Do Cao, Elise Bouderlique, Ivan Nemazanyy, Jean‐Philippe Haymann, Hang‐Korng Ea, Pascal Richette, Michel Daudon, Thomas Bardin, Emmanuel Letavernier","doi":"10.1002/art.70344","DOIUrl":"https://doi.org/10.1002/art.70344","url":null,"abstract":"Objective Gout is the most common form of arthritis, and results from reduced renal excretion of uric acid. A link between environmental pollution and hyperuricemia has been identified, but the underlying mechanisms remain unknown. Our aim was to determine whether the Aryl Hydrocarbon Receptor (AHR), one of the main mediators of the toxicity of environmental pollutants, could be involved in uric acid homeostasis. Methods Murine models based on pharmacological activation of AHR were used, as well as a mouse model with <jats:italic>Ahr</jats:italic> gene knockout, to analyze the impact of this receptor on renal uric acid excretion. Based on the initial results, additional mouse models were used to identify the links between AHR, gluconeogenesis and renal uric acid excretion. A study was also conducted in four patients affected by glycogen storage disease. Results. Activation of AHR by dioxin‐like agonists decreases renal uric acid excretion, while its genetic deletion in mouse models increase renal uric acid excretion. AHR does not modulate renal uric acid transporters, but alters gluconeogenic processes and lactate metabolism in hepatocytes. Lactate is exchanged for uric acid in the renal proximal tubule, reducing renal uric acid excretion. The study in patients confirms that gluconeogenesis is a major determinant of uric acid homeostasis. Conclusion These results highlight the major role of AHR and gluconeogenesis in the regulation of uric acid homeostasis <jats:styled-content>.</jats:styled-content>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"13 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149010081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Diagnosis of Axial Spondyloarthritis Is Associated With Less Long-Term Spinal Structural Damage: A Longitudinal Analysis of the Swiss Clinical Quality Management in Rheumatic Diseases Registry.","authors":"Annik Steimer, Jonas Brändli, Mauro Bachmann, Andrea Götschi, Claudia L Rodrigues, Michael J Nissen, Burkhard Möller, Kristina Bürki, Martin Wendiggensen, Simon Grosswiler, Michael Andor, Diana Dan, Frauke Förger, Sabine Adler, Diego Kyburz, Oliver Distler, Raphael Micheroli, Sofia Ramiro, Adrian Ciurea","doi":"10.1002/art.70346","DOIUrl":"10.1002/art.70346","url":null,"abstract":"<p><strong>Objective: </strong>The Assessment of SpondyloArthritis international Society recently defined early axial spondyloarthritis (axSpA) as a duration of two years or less of axial symptoms. Previous studies have shown no significant difference in short-term outcomes between patients with early and established axSpA treated with biologic/targeted synthetic disease-modifying antirheumatic drugs. To evaluate long-term outcomes, we compared spinal radiographic progression between patients with early and established axSpA who were observed under standard of care treatment in a large Swiss cohort.</p><p><strong>Methods: </strong>Patients with axSpA who had at least two sets of spinal radiographs between 2004 and 2024 in the Swiss Clinical Quality Management registry were scored with the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) by two readers and an adjudicator in case of disagreement. Longitudinal radiographic progression between early and established axSpA was compared (from the time of diagnosis) using a four-parametric logistic model, accounting for the nonlinear progression of mSASSS.</p><p><strong>Results: </strong>Among 376 patients with 1,181 sets of radiographs, 138 patients had early and 238 had established axSpA. Baseline characteristics were similar between the two groups, with a male predominance (61%) and a high prevalence of HLA-B27 positivity (69%). Mean (SD) overall follow-up was 11.5 (8.6) years. Patients with early axSpA exhibited a lower long-term mSASSS (-3.85 mSASSS units, 95% confidence interval [CI] -7.28 to -0.42) compared with established axSpA. This difference became evident 10 to 15 years after diagnosis. The results remained statistically significant after adjustment for baseline radiographic damage (-5.70 mSASSS units, 95% CI -9.31 to -2.09).</p><p><strong>Conclusion: </strong>Early diagnosis of axSpA is associated with lower long-term spinal structural damage.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Potential of Cluster Analysis in Identifying Disease Phenotypes in Calcium Pyrophosphate Deposition: Moving From Intuition to Insight.","authors":"Greta Pellegrino, Laurène Norberciak, Silvia Sirotti, Abhishek Abhishek, Mariano Andrès, Edoardo Cipolletta, Julien Damart, Renaud Desbarbieux, Pilar Diez, Vincent Ducoulombier, Hang-Korng Ea, Emilio Filippucci, Charlotte Jauffret, Augustin Latourte, Jean-Guillaume Letarouilly, Sébastien Ottaviani, Laura Pezzoni, Pascal Richette, Pierre Robinet, Georgios Filippou, Tristan Pascart","doi":"10.1002/art.70345","DOIUrl":"10.1002/art.70345","url":null,"abstract":"<p><strong>Objective: </strong>Calcium pyrophosphate deposition (CPPD) disease is a heterogeneous condition and is frequently misdiagnosed due to the different clinical presentations and variable disease progression. Aim of this study is to identify clinical phenotypes of CPPD disease by integrating real-world data from two data sets.</p><p><strong>Methods: </strong>Data from the COLCHICORT trial and CHRONIC CPPD European observational cohort were analyzed. Multiple correspondence analysis (MCA) was employed to evaluate and visualize the association between modalities of quantitative variables. Hierarchical clustering on principal components were obtained from MCA-identified clusters based on Ward agglomeration method with Euclidean distance. A bivariate analysis between clusters was then performed to characterize the clusters numerically.</p><p><strong>Results: </strong>A total of 134 patients were included in the analysis, resulting in four distinct clusters. Cluster 1 had predominantly monoarticular involvement, frequent recurrent flares, older age at onset, female prevalence, and high C-reactive protein (CRP) levels. Cluster 2 also involved monoarticular cases but with persistent arthritis and onset after 60 years, with about half exhibiting elevated CRP. Cluster 3 included polyarticular cases, featuring persistent arthritis and lower CRP levels, whereas cluster 4 highlighted polyarticular involvement (spine and shoulder included) and primarily recurrent flares.</p><p><strong>Conclusion: </strong>In conclusion, by using for the first time a robust, data-driven methodology based on real-world data, two clusters similar to the EULAR phenotypes \"acute CPP crystal arthritis,\" and \"chronic CPP crystal inflammatory arthritis\" were confirmed, but in addition, two more clusters that do not correspond to any existing EULAR phenotypes were also identified. Due to the characteristics of the cohorts, the osteoarthritis plus CPPD cluster has not been explored.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptomic Profiling in Skeletal Muscle Identifies Associations With Knee Osteoarthritis: the Study of Muscle, Mobility and Aging (SOMMA)","authors":"Daniel S. Evans, Tyler A. Mansfield, Gina M. Many, Tyler J. Sagendorf, Samaneh Farsijani, Bret H. Goodpaster, Lauren M. Sparks, Nancy E. Lane","doi":"10.1002/art.70341","DOIUrl":"https://doi.org/10.1002/art.70341","url":null,"abstract":"Objectives The association between skeletal muscle gene expression and knee osteoarthritis (OA) was examined among older adult participants of the Study of Muscle, Mobility and Aging (SOMMA). Methods Inclusion criteria included knee radiographs and bulk RNA sequencing (RNAseq) in <jats:italic>vastus lateralis</jats:italic> muscle, resulting in 523 participants (56% female). Radiographic knee OA was determined by Kellgren‐Lawrence (KL) grades. Differential gene expression was analyzed using a control group (KL ≤ 1, n = 326) and two nested case groups: (a) KL ≥ 2 (n = 197), (b) KL ≥ 3 (n = 112). Results Compared with controls, there were 27 and 41 genes associated (FDR ≤ 0.05) with KL ≥ 2 and KL ≥ 3, respectively, and 16 genes significantly associated in both contrasts. For 15 of the 16 genes, the association magnitude was larger with more severe OA (KL ≥ 3). Genes associated in both contrasts included brain‐derived neurotrophic factor (BDNF) and interferon regulatory factor‐2 (IRF2). Gene sets enriched in KL ≥ 2 and KL ≥ 3 contrasts included DNA repair and branched chain amino acid (BCAA) catabolism. Conclusions Our results in older adult SOMMA participants indicate that knee OA is associated with genes and pathways expressed in skeletal muscle that are involved in pain sensitization, BCAA catabolism, muscle function preservation, calcium transport and storage, inflammation, and extracellular matrix remodeling. Additional longitudinal studies will be needed to determine how these genes could affect the progression of knee OA. <jats:boxed-text content-type=\"graphic\" position=\"anchor\"> <jats:graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" mimetype=\"image/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic/art70341-toc-0001-m.png\"> <jats:alt-text>image</jats:alt-text> </jats:graphic> </jats:boxed-text>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"2 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148979467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria","authors":"Kerem Abacar, Ala Altaie, Andrew Barr, Sarah L. Mackie, Kulveer Mankia, Dennis McGonagle","doi":"10.1002/art.70339","DOIUrl":"https://doi.org/10.1002/art.70339","url":null,"abstract":"‐","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"382 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148979469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatology Informatics System for Effectiveness (RISE) Registry Participation Associated with Significant Gains in Quality Measure Performance: An Interrupted Time Series Analysis","authors":"Gabriela Schmajuk, Jessica Fitzpatrick, Jing Li, Stephen Shiboski, Emma Kersey, Jinoos Yazdany","doi":"10.1002/art.70340","DOIUrl":"https://doi.org/10.1002/art.70340","url":null,"abstract":"Objective To examine the association between participation in a qualified clinical data registry and quality measure performance. Methods We included practices that joined the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) registry between 2015 – 2021. We calculated annual performance on 4 primary measures and 2 control measures starting 12 months before through 18 months after enrollment. We used an interrupted time‐series (ITS) analysis to assess changes in practice‐level performance before and after RISE enrollment overall and stratified by practices’ baseline performance. Results We included 85 practices caring for 331,975 patients. Overall, performance on all primary measures improved during the study period, although RISE enrollment was associated with a significantly greater improvement rate in 1 of the 4 primary measures (RA functional status assessment (slope difference 0.88 percentage points/month; p=0.006). Practices with baseline lower performance had significantly greater improvements after joining RISE for 3 out of the 4 primary measures compared to high‐performing practices, including RA functional status assessment, TB screening prior to biologic therapy, and osteoporosis screening. Conclusions RISE enrollment was associated with significant improvements in 3 out of 4 rheumatology‐specific quality measures for practices with lower baseline performance. These findings suggest that registry participation may accelerate uptake of best practices and narrow performance gaps across sites. Future work is needed to understand the mechanisms underlying these improvements.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"88 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148979470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}